173 related articles for article (PubMed ID: 9528833)
1. Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma.
Nakano T; Chahinian AP; Shinjo M; Tonomura A; Miyake M; Togawa N; Ninomiya K; Higashino K
Br J Cancer; 1998 Mar; 77(6):907-12. PubMed ID: 9528833
[TBL] [Abstract][Full Text] [Related]
2. Intrapleural administration of tumour necrosis factor-alpha (TNFalpha) in patients with mesothelioma: cytokine patterns and acute-phase protein response.
Stam TC; Swaak AJ; Kruit WH; Stoter G; Eggermont AM
Eur J Clin Invest; 2000 Apr; 30(4):336-43. PubMed ID: 10759883
[TBL] [Abstract][Full Text] [Related]
3. The Correlation of Serum Mesothelin Level With Pleural Thickness in Malignant Pleural Mesothelioma Makes it a Valuable Tool for Monitoring Tumor Progression.
Fontana V; Vigani A; Pistillo MP; Giannoni U; Rosemberg I; Canessa PA; Berisso G; Ferro P; Franceschini MC; Tonarelli M; Roncella S
J Thorac Oncol; 2019 May; 14(5):e92-e94. PubMed ID: 31027749
[No Abstract] [Full Text] [Related]
4. Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients.
Castagneto B; Zai S; Mutti L; Lazzaro A; Ridolfi R; Piccolini E; Ardizzoni A; Fumagalli L; Valsuani G; Botta M
Lung Cancer; 2001; 31(2-3):303-10. PubMed ID: 11165411
[TBL] [Abstract][Full Text] [Related]
5. Effect of IL-6 elevation in malignant pleural effusion on hyperfibrinogenemia in lung cancer patients.
Yamaguchi T; Kimura H; Yokota S; Yamamoto Y; Hashimoto T; Nakagawa M; Ito M; Ogura T
Jpn J Clin Oncol; 2000 Feb; 30(2):53-8. PubMed ID: 10768866
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of soluble CD26 in malignant pleural mesothelioma.
Fujimoto N; Ohnuma K; Aoe K; Hosono O; Yamada T; Kishimoto T; Morimoto C
PLoS One; 2014; 9(12):e115647. PubMed ID: 25526639
[TBL] [Abstract][Full Text] [Related]
7. High pleural fluid hyaluronan concentrations in rheumatoid arthritis.
Söderblom T; Pettersson T; Nyberg P; Teppo AM; Linko L; Riska H
Eur Respir J; 1999 Mar; 13(3):519-22. PubMed ID: 10232419
[TBL] [Abstract][Full Text] [Related]
8. Use of Serum Mesothelin as an Indicator of Tumor Progression in Routine Clinical Practice of Malignant Pleural Mesothelioma Treatment.
Vigani A; Pistillo MP; Fontana V; Giannoni U; Rosenberg I; Canessa PA; Berisso G; Ferro P; Franceschini MC; Tonarelli M; Roncella S
J Thorac Oncol; 2018 Aug; 13(8):e143-e145. PubMed ID: 30049376
[No Abstract] [Full Text] [Related]
9. [The kinetics of IL-2 after pleural administration in the treatment of neoplastic pleurisy].
Astoul P; Bertault-Peres P; Durand A; Boutin C
Rev Mal Respir; 1994; 11(1):29-35. PubMed ID: 8128091
[TBL] [Abstract][Full Text] [Related]
10. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
Scherpereel A; Grigoriu B; Conti M; Gey T; Grégoire M; Copin MC; Devos P; Chahine B; Porte H; Lassalle P
Am J Respir Crit Care Med; 2006 May; 173(10):1155-60. PubMed ID: 16456138
[TBL] [Abstract][Full Text] [Related]
11. Interleukin 6 activity in pleural effusion. Its diagnostic value and thrombopoietic activity.
Yokoyama A; Maruyama M; Ito M; Kohno N; Hiwada K; Yano S
Chest; 1992 Oct; 102(4):1055-9. PubMed ID: 1395742
[TBL] [Abstract][Full Text] [Related]
12. Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study.
Goey SH; Eggermont AM; Punt CJ; Slingerland R; Gratama JW; Oosterom R; Oskam R; Bolhuis RL; Stoter G
Br J Cancer; 1995 Nov; 72(5):1283-8. PubMed ID: 7577483
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic value of interleukin-1alpha, interleukin-6, and tumor necrosis factor in pleural effusions.
Xirouchaki N; Tzanakis N; Bouros D; Kyriakou D; Karkavitsas N; Alexandrakis M; Siafakas NM
Chest; 2002 Mar; 121(3):815-20. PubMed ID: 11888965
[TBL] [Abstract][Full Text] [Related]
14. Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma.
Tabata C; Shibata E; Tabata R; Kanemura S; Mikami K; Nogi Y; Masachika E; Nishizaki T; Nakano T
BMC Cancer; 2013 Apr; 13():205. PubMed ID: 23617783
[TBL] [Abstract][Full Text] [Related]
15. Soluble mesothelin related protein in mesothelioma.
Creaney J; Christansen H; Lake R; Musk AB; de Klerk N; Robinson BW
J Thorac Oncol; 2006 Feb; 1(2):172-4. PubMed ID: 17409849
[No Abstract] [Full Text] [Related]
16. Updates in Effusion Cytology.
Lepus CM; Vivero M
Surg Pathol Clin; 2018 Sep; 11(3):523-544. PubMed ID: 30190139
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of interleukin-8 reduces human malignant pleural mesothelioma propagation in nude mouse model.
Galffy G; Mohammed KA; Nasreen N; Ward MJ; Antony VB
Oncol Res; 1999; 11(4):187-94. PubMed ID: 10566617
[TBL] [Abstract][Full Text] [Related]
18. No relationship between tumour infiltrating lymphocytes and overall survival is seen in malignant mesothelioma of the pleura.
Mudhar HS; Fisher PM; Wallace WA
Eur J Surg Oncol; 2002 Aug; 28(5):564-5. PubMed ID: 12217312
[No Abstract] [Full Text] [Related]
19. Thrombocytosis in patients with malignant pleural mesothelioma.
Olesen LL; Thorshauge H
Cancer; 1988 Sep; 62(6):1194-6. PubMed ID: 3409188
[TBL] [Abstract][Full Text] [Related]
20. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
Pass HI; Wali A; Tang N; Ivanova A; Ivanov S; Harbut M; Carbone M; Allard J
Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
